RT info:eu-repo/semantics/article
T1 Mesopic Disability Glare in Stage-Two Dysfunctional Lens Syndrome
A1 Holgueras López, Alfredo
A1 Marcos, Manuel
A1 Martínez Plaza, Elena
A1 López Miguel, Alberto
A1 Mansilla Gallo, Alberto
A1 Maldonado López, Miguel José
AB To analyze visual function under different conditions and glare sources in stage-2 dysfunctional lens syndrome (DLS). Forty patients over 49 years of age with initial bilateral lens opacification (Lens Opacities Classification System III [LOCS-III] scores up to 3), best-corrected visual acuity of 20/25 or better, and no ocular disease were evaluated. Binocular photopic and mesopic contrast sensitivity (CS) with/without halogen and xenon increasing glare sources were analyzed. Mesopic disability glare (MDG) was calculated as the difference between mesopic CS with/without the glare source. The median logarithmic CS (logCS) values were lower under mesopic conditions (1.05) than under photopic illumination (1.65; P < 0.001). Halogen and xenon glare further decreased mesopic CS (both, median logCS 0.75, P < 0.001). The mean MDG was 0.31 ± 0.10 log units for halogen glare and 0.33 ± 0.09 log units for xenon glare. The mesopic CS and MDG were not associated with any photopic test. The mesopic CS with glare but not photopic CS or mesopic CS was correlated with the LOCS-III scores. The best association was provided by MDG, which showed a pooled correlation with LOCS-III nuclear opalescence (r = 0.411, P < 0.001) and cortical scores (r = 0.226, P = 0.04). The mesopic CS under a glare source is an independent early indicator of visual impairment in stage-2 DLS patients, and appears to be substantial. Furthermore, the MDG is more sensitive than photopic and mesopic CS for evaluating patients with initial phacosclerosis. Surgeons should consider this in the decision-making process of the correct timing for lens surgery.
SN 2193-8245
YR 2022
FD 2022
LK https://uvadoc.uva.es/handle/10324/64310
UL https://uvadoc.uva.es/handle/10324/64310
LA spa
NO Mesopic Disability Glare in Stage-Two Dysfunctional Lens Syndrome. Ophthalmol Ther. 2022, vol. 11, n. 2. p.677-687
DS UVaDOC
RD 07-ago-2024